Prognostic Value of Body Mass Index and Serum Lipid for First-line Immunotherapy in Patients with Advanced NSCLC: A Retrospective Study

Growing research demonstrate that obesity promotes tumorigenesis and progression, but majority clinical studies showed that increasing body mass index (BMI) is unexpectedly associated with improved outcomes from immune checkpoint inhibitors (ICIs) in patients with various malignancies, including non-small cell lung cancer (NSCLC). However, the association between BMI and outcomes from first-line immunotherapy in NSCLC is limited and debatable. Moreover, the associations between serum lipids closely related to obesity and outcomes in patient with malignant tumors treated with immunotherapy are unclear.